SiRNA-mediated IGF-1R inhibition sensitizes human colon cancer SW480 cells to radiation

References

• Cohen SJ, Cohen, RB, Meropol NJ. Targeting signal transduction pathways in colorectal cancer–more than skin deep. J Clin Oncol 2005;23:5374–85.
   PubMed Web of Science ®Google Scholar
• Labianca R, Beretta G, Gatta G, Braud F, Wils J. Colon cancer. Crit Rev Oncol Hematol 2004;51:145–70.
   PubMed Web of Science ®Google Scholar
• Ansari R, Mahdavinia M, Sadjadi A, Nouraie M, Kamangar F, Bishehsari F, . Incidence and age distribution of colorectal cancer in Iran. Results of a population-based cancer registry. Cancer Lett 2006;240:143–7.
   PubMedGoogle Scholar
• Sengupta N, Gill KA, Macfie TS, Lai CS, Suraweera N, McDonald S, Silver A. Management of colorectal cancer: A role for genetics in prevention and treatment. Pathol Res Prac 2008;204:469–77.
   PubMed Web of Science ®Google Scholar
• Luebeck EG, Moolgavkar SH. Multistage carcinogenesis and the incidence of colorectal cancer. Proc Natl Acad Sci USA 2002;99:15095–100.
   PubMed Web of Science ®Google Scholar
• Waters C. Colorectal cancer: An overview. Pharmaceut J 2006;276:323–6.
   Google Scholar
• Priebe MG, Vonk RJ, Sun X, He T, Harmsen HJM, Welling GW. The physiology of colonic metabolism possibilities for interventions with pre- and probiotics. Eur J Nutr 2002;41:I2–I10.
   PubMedGoogle Scholar
• Krueger H, McLean D, Williams D. Gastrointestinal cancers. Prog Exp Tumor Res 2008;40:85–91.
   PubMedGoogle Scholar
• Chung-Faye GA, Kerr DJ. Innovative treatment for colon cancer. BMJ 2000;321:1397–9.
   PubMedGoogle Scholar
• Xu R, Zhou B, Fung PC, Li X. Recent advances in the treatment of colon cancer. Histol Histopathol 2006;21:867–72.
   PubMedGoogle Scholar
• Chawla AK, Kachnic LK, Clark JW, Willett CG. Combined modality therapy for rectal and colon cancer. Semin Oncol 2003;30:101–12.
   PubMedGoogle Scholar
• Giovan GG, Luca S, Michele M. New dimensions in cancer biology and therapy. J Cell Physiol 2000;183:284–7.
   PubMedGoogle Scholar
• Voort van Zijp JVD, Hoekstra HJ, Basson MDZ. Evolving management of colorectal cancer. WJG 2008;14:3956–67.
   PubMedGoogle Scholar
• Macarulla T, Ramos FJ, Capdevila J, Saura C, Tabernero J. Novel targets for anticancer treatment development in colorectal cancer. Clin Colorectal Cancer 2006;6:265–72.
   PubMedGoogle Scholar
• Stassen T, Port M, Nuyken I, Abend M. Radiation-induced gene expression in MCF-7 cells. Int J Radiat Biol 2003;79:319–31.
   PubMed Web of Science ®Google Scholar
• Yin E, Nelson DO, Coleman MA, Peterson LE, Wyrobek AJ. Gene expression changes in mouse brain after exposure to low-dose ionizing radiation. Int J Radiat Biol 2003;79:759–75.
   PubMed Web of Science ®Google Scholar
• Paul D, Adly Y, Joseph C, Ruben C, George A, Kristoffer V, . Stress and radiation induced activation of multiple intracellular signalling pathways. Radiat Res 2003;159:283–300.
   PubMedGoogle Scholar
• Schmidt-Ullrich RK, Dent P, Grant S, Mikkelsen RB, Valerie K. Signal transduction and cellular radiation responses. Radiat Res 2000;153:245–57.
   PubMed Web of Science ®Google Scholar
• Kuhn C, Hurwitz SA, Kumar MG, Cotton J, Spandau DF. Activation of the insulin-like growth factor-1 receptor promotes the survival of human keratinocytes following ultraviolet B irradiation. Int J Cancer 1999;80:431–8.
   PubMed Web of Science ®Google Scholar
• Yu D, Shibuya H, Miura M. Roles of the insulin like growth factor 1 receptor C-terminus on cellular radioresistance. Biochem Biophys Res Commun 2003;311:174–8.
   PubMedGoogle Scholar
• Heron-Milhavet L, LeRoith D. Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage. J Biol Chem 2002;277:15600–6.
   PubMedGoogle Scholar
• Ma BBY, Bristow RG, Kim J, Siu LL. Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol 2003;21:2760–76.
   PubMed Web of Science ®Google Scholar
• Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: Overview and recent insights. Endocr Rev 2007;28:20–47.
   PubMed Web of Science ®Google Scholar
• Freier S, Weiss O, Eran M, Flyvbjerg A, Dahan R, Nephesh I, . Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut 1999;44:704–8.
   PubMed Web of Science ®Google Scholar
• Matthias WM, Christian F, Bin LS, Christina JM, Dieter E, Gustavo B, . Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 2002;95:2086–95.
   PubMedGoogle Scholar
• Guo YS, Jin GF, Houston CW, Thompson JC, Townsend Jr. CM. Insulin-like growth factor-I promotes multidrug resistance in MCLM colon cancer cells. J Cell Physiol 1998;175:141–8.
   PubMedGoogle Scholar
• Pfeffer S, Meister G, Landthaler M, Tuschl T. RNA silencing. B.I.F. FUTURA 2005;20:83–90.
   Google Scholar
• Downward J. RNA interference. Br Med J 2004;328:1245–8.
   PubMed Web of Science ®Google Scholar
• Barik S. Silence of the transcripts: RNA interference in medicine. J Mol Med 2005;83:764–73.
   PubMed Web of Science ®Google Scholar
• Grünweller A, Wyszko E, Bieber B, Jahnel R, Erdmann VA, Kurreck J. Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 20-O-methyl RNA, phosphorothioates and small interfering RNA. Nucl Acids Res 2003;31:3185–93.
   PubMed Web of Science ®Google Scholar
• Mittal V. Improving the efficiency of RNA interference in mammals. Nat Rev Genet 2004;5:355–65.
   PubMed Web of Science ®Google Scholar
• Sengupta N, Gill KA, MacFie TS, Lai CS, Suraweera N, McDonald S, Silver A. Management of colorectal cancer: A role for genetics in prevention and treatment. Pathol Res Prac 2008;204:469–77.
   PubMed Web of Science ®Google Scholar
• Cross D, Burmester JK. Gene therapy for cancer treatment: Past, present and future. Clin Med Res 2006;4:218–27.
   PubMedGoogle Scholar
• Guerreiro AS, Boller D, Doepfner KT. IGF-IR: potential role in antitumor agents. Drug News Pers 2006;19:261–72.
   PubMedGoogle Scholar
• Casa AJ, Dearth RK, Litzenburger BC, Lee AV, Cui X. The type I insulin-like growth factor receptor pathway: A key player in cancer therapeutic resistance. Front Biosci 2008;1:3273–87.
   Google Scholar
• Nakanishi Y, Mulshine JL, Kasprzyk PG, Natale RB, Maneckjee R, Avis I, . Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J Clin Invest 1988;82:354–9.
   PubMed Web of Science ®Google Scholar
• Lee CT, Wu S, Gabrilovich D, Chen H, Nadaf-Rahrov S, Ciernik IF, . Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. Cancer Res 1996;56:3038–41.
   PubMedGoogle Scholar
• Chernicky CL, Yi L, Tan H, Gan SU, Ilan J. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo. Cancer Gene Ther 2000;7:384–95.
   PubMedGoogle Scholar
• Tan FL, Yin JQ. RNAi, a new therapeutic strategy against viral infection. Cell Res 2004;14:460–6.
   PubMed Web of Science ®Google Scholar
• Collis SJ, Swartz MJ, Nelson WG, DeWeese TL. Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res 2003;63:1550–4.
   PubMed Web of Science ®Google Scholar
• Rochester MA, Riedemann J, Hellawell GO, Brewster SF, Macaulay VM. Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther 2005;12(1):90–100.
   PubMedGoogle Scholar